Pds biotech announces participation in the channelchek takeaway series

Florham park, n.j., jan. 26, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced its participation in the channelchek takeaway series from the j.p. morgan healthcare conference to be broadcast thursday, january 26, starting at 10:00 a.m., est. the event will include an overview of pds biotech's business and clinical development strategy from frank k. bedu-addo, ph.d., president and ceo, followed by a question and answer session with noble capital markets' senior analyst robert leboyer.
PDSB Ratings Summary
PDSB Quant Ranking